[go: up one dir, main page]

MX2009008073A - Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados. - Google Patents

Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados.

Info

Publication number
MX2009008073A
MX2009008073A MX2009008073A MX2009008073A MX2009008073A MX 2009008073 A MX2009008073 A MX 2009008073A MX 2009008073 A MX2009008073 A MX 2009008073A MX 2009008073 A MX2009008073 A MX 2009008073A MX 2009008073 A MX2009008073 A MX 2009008073A
Authority
MX
Mexico
Prior art keywords
metabolic syndrome
related disorders
treatment
epoxide hydrolase
soluble epoxide
Prior art date
Application number
MX2009008073A
Other languages
English (en)
Inventor
Heather Kay Webb Hsu
Original Assignee
Arete Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arete Therapeutics Inc filed Critical Arete Therapeutics Inc
Publication of MX2009008073A publication Critical patent/MX2009008073A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describen los compuestos, composiciones y métodos para inhibir el comienzo del síndrome metabólico y el tratamiento de trastornos relacionados en un sujeto en necesidad de dicha terapia.
MX2009008073A 2007-01-29 2008-01-28 Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados. MX2009008073A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88712407P 2007-01-29 2007-01-29
PCT/US2008/052226 WO2008094869A1 (en) 2007-01-29 2008-01-28 Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders

Publications (1)

Publication Number Publication Date
MX2009008073A true MX2009008073A (es) 2009-08-12

Family

ID=39400919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008073A MX2009008073A (es) 2007-01-29 2008-01-28 Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados.

Country Status (13)

Country Link
US (1) US20080221105A1 (es)
EP (1) EP2124917A1 (es)
JP (1) JP2010516787A (es)
KR (1) KR20090111319A (es)
CN (1) CN101594858A (es)
AU (1) AU2008210730A1 (es)
BR (1) BRPI0807829A2 (es)
CA (1) CA2675450A1 (es)
EA (1) EA200901062A1 (es)
IL (1) IL199655A0 (es)
MX (1) MX2009008073A (es)
TW (1) TW200932224A (es)
WO (1) WO2008094869A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197916A1 (en) * 2007-01-29 2009-08-06 Arete Therapeutics, Inc Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8809552B2 (en) 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
CN113402447B (zh) * 2021-06-22 2022-10-18 沈阳药科大学 一种sEH抑制剂或其药学上可接受的组合物及其制备方法和应用
CN116924966A (zh) * 2023-07-19 2023-10-24 沈阳药科大学 美金刚衍生物及其制备方法和在制备治疗可溶性环氧化物酶介导的疾病的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174695B1 (en) * 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
ES2292770T3 (es) * 2001-06-29 2008-03-16 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de fenilpirazoles en calidad de inhibidores de epoxido hidrolasa solubles.
DE10135027A1 (de) * 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
CA2520763A1 (en) * 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US20050164951A1 (en) * 2003-04-03 2005-07-28 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US20060148744A1 (en) * 2004-09-23 2006-07-06 Regents Of The University Of California Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke
JP2008517072A (ja) * 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤
CA2592941A1 (en) * 2005-01-10 2006-08-17 Regents Of The University Of California Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors
JP2008540433A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシドヒドロラーゼインヒビター及びその使用方法
EP1885361A2 (en) * 2005-05-06 2008-02-13 Boehringer Ingelheim International GmbH Acyl hydrazones for treating cardiovascular diseases
US8242170B2 (en) * 2005-06-06 2012-08-14 The Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
ATE450526T1 (de) * 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble

Also Published As

Publication number Publication date
US20080221105A1 (en) 2008-09-11
KR20090111319A (ko) 2009-10-26
WO2008094869A1 (en) 2008-08-07
IL199655A0 (en) 2010-04-15
TW200932224A (en) 2009-08-01
JP2010516787A (ja) 2010-05-20
CA2675450A1 (en) 2008-08-07
EP2124917A1 (en) 2009-12-02
EA200901062A1 (ru) 2009-12-30
BRPI0807829A2 (pt) 2014-08-05
AU2008210730A1 (en) 2008-08-07
CN101594858A (zh) 2009-12-02

Similar Documents

Publication Publication Date Title
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
TN2009000224A1 (en) Inhibitors of akt activity
SG10201811480WA (en) Therapeutic compounds and compositions
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
MX2012000817A (es) Tratamiento para desordenes del higado con inhibidores pi3k.
WO2008137633A3 (en) Methods of modulating cellular homeostatic pathways and cellular survival
WO2011022489A3 (en) (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
EA201890768A2 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
MX342128B (es) Compuestos farmaceuticos.
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
WO2009105217A3 (en) Complement inhibitors as therapeutic agents for treatment of cancer
TN2012000205A1 (en) Method and compositions for treating solid tumors and other malignancies
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal